Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma (NCT00004088), a na phase 2 study. The primary outcome is Best Response Prior to Tandem Autologous Stem Cell Transplant.

2. Clinical Question

3. Trial Design

The registry classifies this as a phase II, single-group study with no masking. Allocation is listed as not applicable, consistent with the absence of a separate randomized comparator. The study is marked completed. The registry reports enrollment of 77 and identifies City of Hope Medical Center as the sponsor.

The intervention is a multimodal treatment sequence rather than one isolated drug. The record names high-dose melphalan, busulfan, and cyclophosphamide; peripheral blood progenitor or stem cell rescue; filgrastim; recombinant interferon alfa; pamidronate disodium; and thalidomide. The arm description begins with high-dose melphalan followed by reinfusion of peripheral blood progenitor cells and filgrastim, but the description is truncated. The full schedule and details of later treatment steps are not reported in the registry record.

The registry gives a study start of 1999-07-08 and a primary completion date of 2018-01-09. Those dates describe the record’s study timeline, but do not establish the duration of follow-up for each participant. Participant-level follow-up duration is not reported in the registry record.

The primary outcome is a participant count classified by best response before the first cycle of tandem autologous stem cell transplant. The record lists six outcome measures, but does not provide results for the primary response categories in the information available. The registry reports 0 analyses. It does not report a detailed statistical analysis plan, the rationale for the enrollment target, or whether any interim analyses were planned or conducted.

This design can describe outcomes observed in the enrolled group, if those outcomes are reported. Without a concurrent comparator, it cannot by itself separate treatment effects from other explanations for observed changes, such as the course of the disease or differences among participants.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Best Response Prior to Tandem Autologous Stem Cell Transplant, measured over From enrollment in the study until day -8: before dilantin given pre-first high-dose chemo preceeding first cycle of tandem autologous cell transplant.

The primary endpoint is the best response recorded from enrollment through the specified point before the first cycle of tandem autologous stem cell transplant. It is expressed as a count of participants, with response categories defined by the Blade criteria cited in the registry description. The categories include complete response, very good partial response, partial response, stable disease, progressive disease, and relapse. The descriptions use changes in myeloma protein and urine M-component, along with bone, calcium, and marrow findings, to distinguish categories.

A best-response endpoint condenses measurements taken over a defined treatment period into a participant-level classification. It can describe the range of responses recorded before a later treatment stage, rather than focusing on only one laboratory value or one measurement date. The registry specifies repeated measurements for serum myeloma protein and urine M-component as part of its criteria.

The endpoint does not itself establish whether treatment caused a response. That requires an appropriate comparison and an analysis that accounts for the study design. Here, no separate comparator is reported. Also, although the registry defines the response categories, it does not give the number of participants assigned to each category. Consequently, the endpoint’s observed results, and their precision, cannot be evaluated from the posted response information.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

What does a participant count represent?

The primary endpoint is a count of participants assigned to response categories. In general, a binary outcome records whether each participant meets a defined condition or does not. A multicategory response outcome retains more detail by sorting participants into several mutually meaningful classifications. The registry describes categories based on the Blade criteria, but the actual category counts are not reported. Consequently, no category proportion or uncertainty measure can be interpreted from the response results in this record.

For any participant count, the denominator matters. It is the number of participants whose outcome could be assessed under the relevant definition. Enrollment is not automatically the denominator for every analysis: participants may have missing measurements, may not reach an assessment time, or may be excluded under rules specified by a protocol. These are general possibilities, not claims about what happened in this study. The registry record does not report the primary endpoint denominator or explain how unevaluable responses were treated.

How should the response criteria be understood?

The registry describes criteria based on changes in serum myeloma protein and urine M-component, with additional conditions involving skeletal lesions, serum calcium, and marrow or blood plasma cells. It also specifies repeated measurement timing for the protein assessments. Such criteria define how observations are translated into response labels; they do not disclose how many participants met each label. Consistent definitions are important because they make the intended outcome classification explicit, but the result still depends on the measurements collected and the rules used when measurements are absent or incomplete. Those operational details beyond the stated criteria are not reported in the registry record.

The categories distinguish different patterns of response or disease status. A participant-level best-response classification summarizes the most favorable category recorded during the specified period, as named by the endpoint. It is not the same as a response measured at one common visit for every participant. The registry does not describe the assessment schedule in enough detail to determine how often assessments occurred or how best response was adjudicated.

What can a single-group design estimate?

In general, a single-group study can describe outcome frequencies among participants who receive the study regimen. A randomized comparator provides a basis for estimating a between-group contrast, subject to the design and analysis assumptions. This registry identifies a single-group model and does not describe a comparator arm. Therefore, no treatment-versus-control contrast can be estimated from the record.

Even when a single-group outcome is precisely measured, precision does not remove the design’s limits for causal interpretation. A confidence interval is a statistical range that conveys uncertainty around an estimate under a specified method. It does not account automatically for differences between a treated group and a hypothetical comparator, nor does it correct for unmeasured factors. No confidence interval for the primary response outcome is reported in the registry record.

Why are analysis details important?

The registry reports 0 analyses. It does not report a statistical model, a planned hypothesis test, an analysis population, or an approach for missing data. A prespecified analysis plan can clarify which participants contribute, how outcomes are summarized, and which comparisons are intended. Without that information, the posted record does not permit evaluation of whether the analysis followed a particular plan or how sensitive the results might be to alternative assumptions.

For binary or categorical outcomes, the number of participants in each outcome category and the denominator for each category are basic descriptive information. If an interval is reported, its method and assumptions matter as well. A normal approximation, exact method, or other approach can yield different uncertainty estimates, especially when counts are limited. No method or interval is reported for the primary endpoint here, so no such result should be inferred.

General concerns such as over-dispersion are most directly relevant to outcomes modeled as counts or rates, where observed variability may exceed the model’s assumptions. The stated primary measure is a participant count classified by response, and the registry does not report a fitted count model. Over-dispersion therefore cannot be assessed from the posted response information. More broadly, the record does not report model diagnostics or sensitivity analyses.

What do planning calculations mean?

Sample-size calculations are planning illustrations based on assumptions about a target effect, variability, significance level, allocation, and analysis method. They are not observed results and do not establish that a study had a particular probability of detecting an effect after the fact. The record describes general planning assumptions for illustrations, including a two-sided significance level of 0.05 and equal allocation between two arms, but the study itself is identified as single group. The registry does not report the rationale for this study’s enrollment or a study-specific power calculation. No planning illustration can substitute for the missing observed response counts or a comparative analysis.

In general, precision depends on the amount of outcome information and the distribution of observations, not only on the enrollment figure. An estimate with limited information may have considerable uncertainty. Since the response counts, endpoint denominator, and uncertainty estimates are not reported, the precision of the primary outcome cannot be determined from the registry record.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists six outcome measures, but the available record does not identify all of them or explain which were prespecified as primary, secondary, or exploratory beyond naming the primary response endpoint. It does not report a multiplicity strategy. In general, evaluating multiple outcomes or multiple comparisons can increase the chance of a misleading positive finding if the analyses are interpreted without accounting for that multiplicity. Whether any adjustment was intended or used is not reported in the registry record.

The registry reports 0 analyses and gives no inferential results for the primary endpoint. It does not report an analysis population, a protocol-defined approach to missing measurements, or rules for participants whose best response could not be classified. It is therefore not possible to determine whether the intended analysis was based on all enrolled participants, only participants with an evaluable response, or another defined group.

Missingness can matter because participants with unavailable assessments may differ from those with complete assessments. General methods include analyzing observed data under stated assumptions, applying imputation procedures, or conducting sensitivity analyses. Which, if any, were used in this study is not reported in the registry record. The relationship between enrollment of 77 and the 68 participants listed as at risk in the adverse-event record is also not explained; these figures should not be treated as interchangeable denominators.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent non-serious adverse event terms

The registry lists one group, titled HD Chemo Followed by PBPC Rescue, with 68 participants at risk in each of the serious and other adverse-event fields. The serious adverse-event field records 0 affected participants, while the other adverse-event field records 68 affected participants. The record also lists 23 deaths. These are separate entries in the registry and should not be combined into a single measure.

The posted information does not give the safety observation period, definitions for the other adverse-event field, attribution rules, or detail about the deaths. It does not say whether the deaths were considered related to treatment, occurred during treatment, or occurred during a specified follow-up period. The record also does not provide event types among the serious adverse events; no top serious-event terms are listed. The 0 serious-event count should therefore be read as the count recorded in this field, not as proof that serious events were impossible or that safety risk was absent.

Because this is a single-group study, these entries do not provide a comparative safety estimate. The adverse-event counts describe what the registry records for the group, with important context about timing and classification not reported in the registry record.

12. What the Result Does, and Does Not, Mean

The registry record establishes that a phase II, single-group study evaluated a multi-part treatment sequence for multiple myeloma and defined a primary outcome based on best response before a later transplant cycle. It also records adverse-event fields for the treatment group. These registry entries describe the study question and some of the outcomes collected; they do not establish a comparative treatment effect.

The primary response criteria are described, but the numbers of participants in each response category are not reported. Without those counts, readers cannot tell from this record how responses were distributed, how often a particular category occurred, or how precise any response estimate might be. The registry reports 0 analyses and does not give an interval estimate or inferential test for the primary response outcome.

The adverse-event entries include 0 participants affected by serious adverse events, 68 affected by other adverse events, and 23 deaths. The record does not report enough detail about timing, event definitions, or attribution to interpret these entries as treatment-caused outcomes. Nor is there a comparison group against which to judge whether those counts differ from another strategy.

In general, an observed outcome in a single group can be useful for describing experience under a regimen, but it cannot isolate the effect of the regimen from other possible explanations. The study includes several interventions, so even a complete outcome report would not identify the separate effect of each drug or procedure. The posted record therefore supports a description of the study design and recorded safety counts, while leaving the main response results and comparative interpretation unresolved.

13. Why This Trial Matters Statistically

Statistically, this record illustrates the distinction between defining an endpoint and reporting an analyzable result. The primary response measure is described in detail, including the criteria used to distinguish response categories. Yet the category counts are not reported. A precise endpoint definition is essential for interpretation, but it cannot replace the observations needed to estimate how frequently each outcome occurred.

The single-group design also shapes what can be learned. Outcomes in a treated group can describe the experience recorded under a complex regimen. Without a concurrent comparator, the design does not estimate how outcomes would differ under another strategy. This limitation applies even when enrollment and follow-up are carefully conducted; it is a consequence of the comparison available in the design, not a judgment about the treatment.

The safety entries further show why denominator, timing, and event definitions matter. The record gives an at-risk count of 68 for safety fields and records 0 serious adverse events, 68 other adverse events, and 23 deaths, but does not explain the observation window or event attribution. Clear counts are informative only when their meaning and scope can be established.

Finally, the record distinguishes study enrollment from the population represented in a particular endpoint. Enrollment is 77, while the safety fields list 68 at risk; the registry does not explain the difference. Reporting outcome-specific denominators, missing-data handling, analysis methods, and uncertainty estimates would help readers assess completeness and precision. Their absence limits statistical interpretation without changing the descriptive details that are recorded.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

Several limitations specific to this study are apparent from the registry record. It identifies a single-group design, with allocation listed as not applicable and masking listed as none. No comparator is described, so the record cannot support a randomized treatment contrast. The regimen includes multiple drugs and a transplant procedure; the contribution of individual components cannot be separated from a single-group result.

The main limitation for interpreting the primary endpoint is that the record defines best response but does not report response-category counts. It also does not report the number of participants with an evaluable primary outcome, how response assessments were timed beyond the stated endpoint window, or how missing or unclassifiable responses were handled. The registry reports 0 analyses and no confidence intervals or other inferential results.

The enrollment figure is 77, whereas the safety fields list 68 participants at risk. The registry record does not explain this difference. The safety information also lacks an observation period, event attribution details, and a description of the other adverse-event field. The 23 deaths cannot be assigned a cause or treatment relationship from the posted information.

The arm description is truncated, so the full administration schedule cannot be reconstructed from the record. The rationale for enrollment, detailed eligibility criteria, analysis plan, and any interim analyses are not reported in the registry record. These omissions limit assessment of the treatment schedule, completeness of outcome reporting, and statistical methods.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma — NCT00004088.
• Registry record last updated 2026-11-03; status last verified 2026-10.
• Results first posted 2019-07-02.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

The registry describes a completed phase II, single-group study sponsored by City of Hope Medical Center, with enrollment of 77. It evaluated a treatment sequence for multiple myeloma involving high-dose chemotherapy, peripheral blood stem cell rescue, and listed biological and drug therapies. The primary endpoint was best response before the first cycle of tandem autologous stem cell transplant, classified using the Blade criteria.

Response-category counts and inferential analyses are not reported in the available record. The adverse-event entry lists 68 participants at risk, 0 affected by serious adverse events, 68 affected by other adverse events, and 23 deaths. Timing and attribution details are not reported. These findings are descriptive registry entries, not a comparison with another treatment.